Tucidinostat and Metronomic Capecitabine for Metastatic Triple-negative Breast Cancer:a Multicenter,Open-label, Randomized Controlled, Phase II Clinical Trial

Clinical trial NCT05390476 · UNKNOWN

Trial details

NCT number: NCT05390476
Sponsor: wang shusen
Status: UNKNOWN
Phase: Phase 2
Study type: INTERVENTIONAL

Triple Negative Breast Cancer

Start date: 2022-08-01
Primary completion: 2024-02-01
Enrollment: 126

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.